-+ 0.00%
-+ 0.00%
-+ 0.00%

*Iovance Biotherapeutics: Current Cash Position, Bolstered by Expense Reductions, Is Expected to Fund Ops Into the 2Q of 2027 >IOVA

Dow Jones·11/06/2025 13:09:00

Please log in to view news